vs
Side-by-side financial comparison of Celldex Therapeutics, Inc. (CLDX) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.
Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $120.0K, roughly 9.5× Celldex Therapeutics, Inc.). Insight Molecular Diagnostics Inc. runs the higher net margin — -2015.4% vs -67764.2%, a 65748.8% gap on every dollar of revenue. On growth, Insight Molecular Diagnostics Inc. posted the faster year-over-year revenue change (-23.4% vs -89.8%). Insight Molecular Diagnostics Inc. produced more free cash flow last quarter ($-7.0M vs $-65.2M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs -12.3%).
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
CLDX vs IMDX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $120.0K | $1.1M |
| Net Profit | $-81.3M | $-23.0M |
| Gross Margin | — | 42.5% |
| Operating Margin | -72628.3% | -2057.5% |
| Net Margin | -67764.2% | -2015.4% |
| Revenue YoY | -89.8% | -23.4% |
| Net Profit YoY | -72.7% | 31.5% |
| EPS (diluted) | $-1.23 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.0K | $1.1M | ||
| Q3 25 | $0 | $260.0K | ||
| Q2 25 | $730.0K | $518.0K | ||
| Q1 25 | $695.0K | $2.1M | ||
| Q4 24 | $1.2M | $1.5M | ||
| Q3 24 | $3.2M | $115.0K | ||
| Q2 24 | $2.5M | $104.0K | ||
| Q1 24 | $156.0K | $176.0K |
| Q4 25 | $-81.3M | $-23.0M | ||
| Q3 25 | $-67.0M | $-10.9M | ||
| Q2 25 | $-56.6M | $-9.7M | ||
| Q1 25 | $-53.8M | $-6.7M | ||
| Q4 24 | $-47.1M | $-33.5M | ||
| Q3 24 | $-42.1M | $-13.5M | ||
| Q2 24 | $-35.8M | $-4.5M | ||
| Q1 24 | $-32.8M | $-9.1M |
| Q4 25 | — | 42.5% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 62.0% | ||
| Q4 24 | — | 40.0% | ||
| Q3 24 | — | 43.5% | ||
| Q2 24 | — | 48.1% | ||
| Q1 24 | — | 25.6% |
| Q4 25 | -72628.3% | -2057.5% | ||
| Q3 25 | — | -4249.2% | ||
| Q2 25 | -8747.5% | -1900.0% | ||
| Q1 25 | -9027.2% | -318.0% | ||
| Q4 24 | -4768.3% | -2262.9% | ||
| Q3 24 | -1633.5% | -11752.2% | ||
| Q2 24 | -1854.2% | -4453.8% | ||
| Q1 24 | -26030.8% | -5265.3% |
| Q4 25 | -67764.2% | -2015.4% | ||
| Q3 25 | — | -4174.6% | ||
| Q2 25 | -7753.4% | -1880.7% | ||
| Q1 25 | -7740.4% | -312.0% | ||
| Q4 24 | -4007.8% | -2255.1% | ||
| Q3 24 | -1320.0% | -11733.0% | ||
| Q2 24 | -1434.8% | -4355.8% | ||
| Q1 24 | -21030.8% | -5186.9% |
| Q4 25 | $-1.23 | $-0.75 | ||
| Q3 25 | $-1.01 | $-0.34 | ||
| Q2 25 | $-0.85 | $-0.30 | ||
| Q1 25 | $-0.81 | $-0.26 | ||
| Q4 24 | $-0.71 | $-2.19 | ||
| Q3 24 | $-0.64 | $-0.98 | ||
| Q2 24 | $-0.54 | $-0.36 | ||
| Q1 24 | $-0.56 | $-1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $518.6M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $527.2M | $-31.5M |
| Total Assets | $583.0M | $25.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $518.6M | $11.6M | ||
| Q3 25 | $583.2M | $18.7M | ||
| Q2 25 | $630.3M | $24.3M | ||
| Q1 25 | $673.3M | $31.0M | ||
| Q4 24 | $725.3M | $8.6M | ||
| Q3 24 | $756.0M | $3.4M | ||
| Q2 24 | $802.3M | $9.3M | ||
| Q1 24 | $823.8M | $5.6M |
| Q4 25 | $527.2M | $-31.5M | ||
| Q3 25 | $598.4M | $-9.2M | ||
| Q2 25 | $655.4M | $1.1M | ||
| Q1 25 | $703.0M | $10.2M | ||
| Q4 24 | $747.0M | $-12.3M | ||
| Q3 24 | $785.9M | $9.7M | ||
| Q2 24 | $813.7M | $22.7M | ||
| Q1 24 | $838.6M | $11.6M |
| Q4 25 | $583.0M | $25.8M | ||
| Q3 25 | $648.4M | $43.9M | ||
| Q2 25 | $692.4M | $50.5M | ||
| Q1 25 | $739.5M | $60.4M | ||
| Q4 24 | $792.3M | $35.1M | ||
| Q3 24 | $823.2M | $70.2M | ||
| Q2 24 | $845.6M | $74.7M | ||
| Q1 24 | $868.8M | $71.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.9M | $-5.5M |
| Free Cash FlowOCF − Capex | $-65.2M | $-7.0M |
| FCF MarginFCF / Revenue | -54350.8% | -616.7% |
| Capex IntensityCapex / Revenue | 1067.5% | 129.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-213.7M | $-25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.9M | $-5.5M | ||
| Q3 25 | $-48.6M | $-4.5M | ||
| Q2 25 | $-44.0M | $-6.3M | ||
| Q1 25 | $-54.4M | $-5.9M | ||
| Q4 24 | $-32.5M | $-5.4M | ||
| Q3 24 | $-55.3M | $-5.5M | ||
| Q2 24 | $-29.3M | $-6.0M | ||
| Q1 24 | $-40.6M | $-3.8M |
| Q4 25 | $-65.2M | $-7.0M | ||
| Q3 25 | $-49.1M | $-5.6M | ||
| Q2 25 | $-44.7M | $-6.6M | ||
| Q1 25 | $-54.6M | $-6.2M | ||
| Q4 24 | $-33.2M | $-5.6M | ||
| Q3 24 | $-55.9M | $-5.6M | ||
| Q2 24 | $-29.6M | $-6.2M | ||
| Q1 24 | $-41.0M | $-3.9M |
| Q4 25 | -54350.8% | -616.7% | ||
| Q3 25 | — | -2135.4% | ||
| Q2 25 | -6127.8% | -1279.5% | ||
| Q1 25 | -7861.4% | -288.4% | ||
| Q4 24 | -2828.3% | -374.5% | ||
| Q3 24 | -1751.2% | -4884.3% | ||
| Q2 24 | -1185.0% | -5931.7% | ||
| Q1 24 | -26270.5% | -2189.8% |
| Q4 25 | 1067.5% | 129.9% | ||
| Q3 25 | — | 403.8% | ||
| Q2 25 | 99.7% | 67.4% | ||
| Q1 25 | 38.1% | 14.4% | ||
| Q4 24 | 64.3% | 14.4% | ||
| Q3 24 | 17.1% | 75.7% | ||
| Q2 24 | 11.0% | 183.7% | ||
| Q1 24 | 220.5% | 13.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
